Welcome to Aurore Life Sciences, a specialized pure-play API manufacturer. As a vital link in pharmaceutical drug manufacturing, we are your trusted partner for all your API & Intermediates requirements. Our unwavering commitment to excellence, innovation, and uncompromising quality sets us apart as leaders in Active Pharmaceutical Ingredient (API) production. With a growing legacy, we are dedicated to advancing healthcare through cutting-edge API manufacturing, empowering formulation manufacturers for a future of continued progress and positive impact.
Our
Aurore’s Key strength is fuelled by early identification, building robust API processes, and targeting early launch opportunities in key markets through complete backward integration. Our capabilities and capacities cater to diverse product markets globally, making us the ideal global partners.
Antiviral
Filing status
CEP/EDMF, TDMF, USDMF
Capacity
200 MT
Anti-Hypertensive
Filing status
CEP/EDMF, MFDS, NMPA, Russia DMF, TPD Canada, USDMF
Capacity
280 MT Annually
Anti Histamine
Filing status
ASMF, USDMF
Capacity
50 MT Annually
Anti-inflammatory
Filing status
Brazil DMF, CEP/EDMF, MFDS, USDMF
Capacity
162 MT Annually
Anti-inflammatory
Filing status
CEP/EDMF, Russia DMF, TPD Canada, USDMF
Capacity
70 MT Annually
Anti-Coagulant
Filing status
CEP/EDMF, USDMF
Capacity
35 MT Annually
Anti-Diabetic
Filing status
Ready to be filed in Key Markets
Capacity
40 MT Annually
Protease Inhibitors
Filing status
Ready to be filed in Key Markets
Capacity
10 MT Annually
Antihypertensive
Filing status
Brazil DMF, MFDS, USDMF
Capacity
96 MT Annually
Anti-Retroviral
Filing status
WHO DMF
Capacity
30 MT Annually
Anti-Arrhythmic
Filing status
ASMF, CEP/EDMF, Israil, MFDS, NMPA, USDMF
Capacity
50 MT Annually
Thrombopoietin Receptor Agonists
Filing status
Ready to be filed in Key Markets
Capacity
30 MT Annually
Anti-Diabetic
Filing status
Commercial
Capacity
20 MT Annually
Mucolytic
Filing status
ASMF, MFDS
Capacity
100MT Annually
Anti-inflammatory
Filing status
ASMF, Egypt DMF, Malaysia DMF, NMPA, Pharmacy And Poision Board, PPB-MOH-KENYA, SAHPRA MOH, Singapore DMF
Capacity
90 MT Annually
Antiviral
Filing status
Indonesia MOH, Malaysia DMF, USDMF, Vietnam
Capacity
50 MT Annually
Antimuscarinics
Filing status
USDMF
Capacity
1.6 MT Annually
Angiotensin II Receptor
Filing status
ASMF, Ready to be filed in Key Markets
Capacity
20 MT Annually
Anti-Arrhythmic
Filing status
CEP/EDMF
Capacity
50 MT Annually
Antihypertensive
Filing status
USDMF
Capacity
5 MT Annually
Anti-Inflammatory
Filing status
USDMF
Capacity
30 MT Annually
Antiviral
Capacity
4 MT Annually
Anti-Epileptic
Filing status
CEP/EDMF, USDMF
Capacity
200 MT Annually
Hypothyroidism
Filing status
CEP/EDMF, NMPA, USDMF
Capacity
1 MT Annually
Hormones
Filing status
CEP/EDMF, Iran DMF, NMPA, USDMF
Capacity
500 KG Annually
Anti-Diabetic
Capacity
28 MT Annually
Angiotensin Receptor Blockers (ARBs)
Filing status
CEP/EDMF
Capacity
10 MT Annually
Veterinary medicine
Filing status
CEP/EDMF, USDMF
Capacity
20 MT Annually
Alzheimer disease
Capacity
2 MT Annually
Antiviral
Filing status
GHANA FDA, Indonesia MOH, Malaysia DMF, Mozambique MOH, RWANDA FDA, SAHPRA MOH, Tanzania MOH, Uganda FDA, Vietnam, WHO DMF
Capacity
5 MT Annually
broad-spectrum, synthetic serine protease inhibitor
Filing status
MFDS, NMPA, USDMF
Capacity
2 MT Annually
oral protease inhibitor
Filing status
WHO DMF
Capacity
4 MT Annually
Anti-Psychotic
Capacity
20 MT Annually
Anti-Allergic
Filing status
ASMF
Capacity
34 MT Annually
Anticonvulsants
Filing status
CEP/EDMF, USDMF
Capacity
40 MT Annually
IBS
Filing status
NMPA
Capacity
40 MT Annually
Anti-Hypertensive
Filing status
USDMF
Capacity
2 MT Annually
selective estrogen receptor modulators (SERMs)
Filing status
CEP/EDMF, MFDS, USDMF
Capacity
15 MT Annually
Antiretroviral medication
Capacity
5 MT Annually
Sedative
Filing status
Iran DMF
Capacity
500 KG Annually
Category C
Filing status
MFDS
Capacity
40 MT Annually
Antiviral
Capacity
1 MT Annually
Antiviral
Capacity
100 MT Annually
Angiotensin Receptor Neprilysin Inhibitor (ARNI)
Capacity
150 MT Annually
Anti-Inflammatory
Filing status
USDMF
Capacity
200 MT Annually
Anti-Allergic/ Anti-Asthma
Filing status
CEP/EDMF
Capacity
100 MT Annually
Anti-inflammatory
Filing status
USDMF
Capacity
30 MT Annually
Transthyretin Stabilizer
Filing status
USDMF
Capacity
1,800 MT Annually
Anti-Retroviral
Filing status
ASMF, Ready to be filed in Key Markets
Capacity
100 MT Annually
Immunosuppressant
Filing status
NMPA, USDMF
Capacity
10 MT Annually
Diuretic
Filing status
ASMF, NMPA, USDMF
Capacity
10 MT Annually
Antiviral
Filing status
Brazil DMF, CEP/EDMF, Iran DMF, PPB-MOH-KENYA, Singapore DMF, TGA DMF, USDMF
Capacity
50 MT Annually
Antiviral
Filing status
Malaysia DMF, NMPA, USDMF
Capacity
30 MT Annually
Anti-Arrhythmic
Filing status
CEP/EDMF, NMPA, USDMF
Capacity
40 MT Annually
Disclaimer: No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.
Quality is the cornerstone of our operations. Our stringent quality control measures ensure that each API is manufactured to the highest standards, fostering trust and confidence in our partners and end-users alike.
Embracing innovation, we constantly push the boundaries of API manufacturing. Our research and development teams collaborate seamlessly to create cutting- edge solutions that address the evolving needs of the pharmaceutical industry.
We adhere to rigorous regulatory guidelines across all phases of production. Our commitment to compliance guarantees that every API leaving our facilities is safe, reliable, and ready for integration into pharmaceutical formulations.
At Aurore Life Sciences, we view our clients as partners on a shared journey. Our collaborative approach ensures that we understand your unique requirements, enabling us to tailor our services to your specific needs.
With a global footprint, we are strategically positioned to serve clients worldwide while maintaining a localized and personalized touch in all interactions.